Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 78 |
| Active Pipeline (Recruiting Now) | 26 (11) |
| Completed vs Stopped Early | 48 / 4 (5.1%) |
| Median Closed Actual Enrollment | 87 participants |
| Physical Hospital Site Disclosure | 96.9% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 10 (6 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Boston Children's Hospital | Boston, MA | 22 |
| Queensland Children's Hospital | South Brisbane, Queensland | 20 |
| The Hospital for Sick Children | Toronto, Ontario | 17 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT04786262 | A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes | Phase III | RECRUITING |
| NCT06619860 | Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy | Phase II | RECRUITING |
| NCT07204275 | Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN) | Phase II/III | RECRUITING |
| NCT06628908 | Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy | Phase III | RECRUITING |
| NCT05422222 | Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age | Phase III | ACTIVE NOT RECRUITING |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Vertex Pharmaceuticals across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the Vertex Pharmaceuticals Interactive Dossier, benchmark peers in Respiratory and Pulmonary, or review the Healthcare Price & Patent Cliff Crosswalk.